Drug Profile
Research programme: immunostimulating gene therapy - Multimeric Biotherapeutics
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Multimeric Biotherapeutics
- Class Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural, Injection)
- 28 Oct 2011 Preclinical development is ongoing